Symptom assessment tools for gastroesophageal reflux disease (GERD) treatment

Journal of Clinical Gastroenterology

Volumn 41, Issue 5, 2007, Pages 437-444

  Fass, Ronnie ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

Gastroesophageal reflux disease (GERD); Heartburn; Proton pump inhibitors; Quality of life

Indexed keywords

ANTACID AGENT; ESOMEPRAZOLE; PROTON PUMP INHIBITOR;

CORRELATION COEFFICIENT; DISEASE SEVERITY; ECONOMIC ASPECT; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MEDICAL ASSESSMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SHORT FORM 36; STOMACH PAIN; TEST RETEST RELIABILITY; VALIDATION PROCESS; WELLBEING;

GASTROESOPHAGEAL REFLUX; HEALTH STATUS INDICATORS; HUMANS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 34247395486     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31802e849f     Document Type: Review

References (61)

1. Dent J, El-Serag H, Wallander M. Epidemiology of gastrooesophageal reflux disease: a systematic review. Gut. 2005;54:710-717.
2. Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol. 2005;3:543-552.
3. Holtmann G. Reflux disease: the disorder of the third millennium. Eur J Gastroenterol Hepatol. 2001;13(suppl 1):S5-S11.
4. Delaney B. Review article: prevalence and epidemiology of gastrooesophageal reflux disease. Aliment Pharmacol Ther. 2004;20(suppl 8):2-4.
5. Goh K. Changing epidemiology of gastroesophageal reflux disease in the Asian-Pacific region: an overview. J Gastroenterol Hepatol. 2004;19(suppl 3):S22-S25.
6. Altman K, Stephens R, Lyttle C, et al. Changing impact of gastroesophageal reflux in medical and otolaryngology practice. Laryngoscope. 2005;115: 1145-1153.
7. Wong W, Fass R. Extraesophageal and atypical manifestations of GERD. J Gastroenterol Hepatol. 2004;19(suppl 3):S33-S43.
8. Vakil N. Treatment of gastroesophageal reflux disease: defining endpoints that are important to patients. Rev Gastroenterol Disord. 2004;4(suppl 4):S3-S7.
9. De la Loge C, Trudeau E, Marquis P, et al. Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL. Qual Life Res. 2004;13:1751-1762.
10. Delg' Innocenti A, Guyatt G, Wiklund I, et al. The influence of demographic factors and health-related quality of life on treatment satisfaction in patients with gastroesophageal reflux disease treated with esomeprazole. Health Qual Life Outcomes. 2005;3:4.
11. Amouretti M, Nalet B, Robaszkiewicz M, et al. Validation of the short-form REFLUX-QUAL, a gastro-esophageal reflux disease (GERD) specific quality of life questionnaire. Gastroenterol Clin Biol. 2005;29:793-801.
12. Holtmann G, Chassany O, DeVault K, et al. Validation of a new scale for the assessment of health related quality of life in gastroesophageal reflux disease (GERD). Gut. 2005;54(suppl VII):A-52.
13. Coyne K, Wiklund I, Schmier J, et al. Primary care physicians' perceptions and practices on the management of GERD: results of a national survey. Aliment Pharmacol Ther. 2003;18:907-915.
14. Shikiar R, Flood E, Siddique R, et al. Development and validation of the gastroesophageal reflux disease treatment satisfaction questionnaire. Dig Dis Sci. 2005;50:2025-2033.
15. Klauser A, Schindlbeck N, Muller-Lissner S. Symptoms in gastrooesophageal reflux disease. Lancet. 1990;335:205-208.
16. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management-the Genval Workshop Report. Gut. 1998;44(suppl 2):S1-S16.
17. Locke G, III, Talley N, Fett S, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, MN. Gastroenterology. 1997;112:1148-1156.
18. European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit. CPMP/ICH/363/96. ICH Topic E9. Statistical Principles for Clinical Trials. Step 4, Consensus guideline. 1998.
19. Stanghellini V, Armstrong D, Monnikes H, et al. Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther. 2004;19:463-479.
20. Allen C, Parameswaran K, Belda J, et al. Reproducibility, validity, and responsiveness of a disease-specific symptom questionnaire for gastroesophageal reflux disease. Dis Esophagus. 2000;13:265-270.
21. Dimenas E, Glise H, Hallerack B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol. 1993;28:681-687.
22. Rothman M, Farup C, Stewart W, et al. Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci. 2001;46:1540-1549.
23. Revicki D, Wood M, Wiklund I, et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998;7:75-83.
24. Svedlund J, Sjodin I, Dovetall G. GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33:129-134.
25. Talley N, Fullerton S, Junghard O, et al. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol. 2001;96:1998-2004.
26. Williford W, Krol W, Spechler S. Development for and results of the use of a gastroesophageal reflux disease activity index as an outcome variable in a clinical trial. VA Cooperative Study Group of Gastroesophageal Reflux Disease (GERD). Contron Clin Trials. 1994; 15:335-348.
27. Pare P, Meyer F, Armstrong D, et al. Validation of the GSFQ, a self-administered symptom frequency questionnaire for patients with gastroesophageal reflux disease. Can J Gastroenterol. 2003;17:307-312.
28. Wong W, Lam K, Lai K, et al. A validated symptoms questionnaire (Chinese GERDQ) for the diagnosis of gastro-oesophageal reflux disease in the Chinese population. Aliment Pharmacol Ther. 2003;17:1407-1413.
29. Nocon M, Kulig M, Leodolter A, et al. Validation of the reflux disease questionnaire for a German population. Eur J Gastroenterol Hepatol. 2005;17:229-233.
30. Liu J, Woloshin S, Laycock W, et al. Symptoms and treatment burden of gastroesophageal reflux disease: validating the GERD assessment scales. Arch Intern Med. 2004;11:2058-2064.
31. Rentz A, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13:1737-1749.
32. Revicki D, Rentz A, Tack J, et al. Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders. Clin Gastroenterol Hepatol. 2004;2:769-777.
33. Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39:888-891.
34. Armstrong D, Veldhuyzen van Zanten S, Chung S, et al. Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test. Can J Gastroenterol. 2005;19:350-358.
35. Armstrong D, Monnikes H, Bardhan K, et al. The construction of a new evaluative GERD questionnaire-methods and state of the art. Digestion. 2004;70:71-78.
36. Stanghellini V. ReQuest™: new dimensions in the assessment and management of GERD. Drugs Today. 2005;41(suppl B):7-11.
37. Monnikes H, Bardhan K, Stanghellini V, et al. Evaluation of GERD symptoms during therapy. Part II. Psychometric evaluation and validation of the new questionnaire ReQuest™ in erosive GERD. Digestion. 2004;69:238-244.
38. Bardhan K, Stephens R, Armstrong D, et al. International validation of ReQuest™ in patients with endoscopy negative gastroesophageal reflux disease. Aliment Pharmacol Ther. 2004;20:891-898.
39. Bardhan K, Stanghellini V, Armstrong D, et al. Evaluation of GERD symptoms during therapy. Part I. Development of the new GERD Questionnaire ReQuest™. Digestion. 2004;69:229-237.
40. Puhan M, Guyatt G, Armstrong D, et al. Validation of a symptom diary for patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23:531-541.
41. Damiano A, Handley K, Adler E, et al. Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS). Dig Dis Sci. 2002;47:1530-1537.
42. Damiano A, Siddique R, Xu X. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. Dig Dis Sci. 2003;48:657-662.
43. Spechler S. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med. 1992;326:786-792.
44. Spechler S, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001;285:2331-2338.
45. Kleinman L, Faull R, Walker R, et al. Gastrointestinal-specific patient-reported outcome instruments differentiate between renal transplant patients with or without GI complications. Transplant Proc. 2005;37:846-849.
46. Talley N, Moore M, Sprogis A, et al. Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. MJA. 2002;177:423-427.
47. Kulich K, Regula J, Stasiewicz J, et al. Psychometric validation of the Polish translation of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) Questionnaire in patients with reflux disease. Pol Arch Med Wewn. 2005;113:241-249.
48. Pacini F, Calabrese C, Cipolletta L, et al. Burden of illness in Italian patients with gastro-oesophageal reflux disease. Curr Med Res Opin. 2005;21:495-502.
49. Muramatsu A, Azuma T, Okajima T, et al. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan. Aliment Pharmacol Ther. 2004;20(suppl 1):102-106.
50. Kulich K, Ujazaszy L, Toth G, et al. Psychometric validation of the Hungarian translation of the gastrointestinal symptom rating scale (GSRS) and quality of life in reflux and dyspepsia (QOLRAD) questionnaire in patients with reflux disease. Orv Hetil. 2004;145 (13 suppl 2):723-729, 739-744.
51. Pique J, Kulich K, Vagazoc O, et al. Burden of gastroesophageal reflux disease. Evidence from a recent methodological study in Spain. Gastroenterol Hepatol. 2004;27:300-306.
52. Kulich K, Malfertheiner P, Madisch A, et al. Psychometric validation of the German translation of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in patients with reflux disease. Health Qual Life Outcomes. 2003;1:62.
53. Revicki D, Sorensen S, Maton P, et al. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis. 1998;16:284-291.
54. Locke G, Talley N, Weaver A, et al. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc. 1994;69:539-547.
55. Shaw M, Talley N, Beebe T, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol. 2001;96:52-57.
56. Monnikes H, Bardhan K, Pfaffenberger B, et al. Pantoprazole 20mg is at least as effective as esomeprazole 20 mg for first and sustained symptom relief in patients with endoscopic-negative gastroesophageal reflux disease (EnGERD). Gut. 2003;52(suppl VI):A127.
57. Van Rensburg C, Bardhan K, Tulassay Z, et al. Pantoprazole 40mg is comparable to esomeprazole 40 mg on first and sustained symptom relief in patients with erosive gastroesophageal reflux disease (GERD). Gastroenterology. 2005;128(4 suppl 2):A530.
58. Stanghellini V, Armstrong D, Monnikes H, et al. Determination of ReQuest™-based symptom thresholds to define symptom relief in GERD clinical studies. Digestion. 2005;71:145-151.
59. Stanghellini V, Armstrong D, Monnikes H, et al. Objective definition of symptom relief in clinical studies: determination of international GERD symptom thresholds based on ReQuest™. Gastroenterol. 2006;130(suppl 2):A455.
60. Bardhan K, Armstrong D, Fass R, et al. The ReQuest™/LA- classification: a novel integrated approach for the comprehensive assessment of treatment outcome of gastroesophageal reflux disease (GERD). Can J Gastroenterol. 2005;19(suppl C):R.0031.
61. Junghard O, Lauritsen K, Talley N, et al. Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non ulcer dyspepsia. Eur J Surg. 1998;583(suppl):106-111.